AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04163406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ferrous fumarate
Description: Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate
Study NCT02894398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 25mg/daily, oral intake
Study NCT02894398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered as basic therapy (commercially available injection, obtained from local pharmacies) as followed: 500mg/once monthly, intramuscular injection
Study NCT03669887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification Program
Description: The intervention will consist of 5 individual face-to-face sessions at 2-weekly intervals with a dietitian with experience in lifestyle modification program, followed by monthly phone contact and smartphone text messages. All study participants in the intervention arm will also be arranged to meet with an exercise instructor at least once during the LMP on the same day as one of the dietitian appointment. Ongoing support from the exercise instructor will also be available by phone calls or emails.
Study NCT04163406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ferrous fumarate + GOS
Description: Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and GOS (3g)
Study NCT04163406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ferrous fumarate + HMOs
Description: Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and HMOs (2'-FL (2g) + LNnT(1g))
Study NCT05231863 — intervention group
Intervention type: DRUG
Intervention: TKIs
Description: tyrosine kinase inhibitors based therapy
Study NCT04000555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vancomycin
Description: Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics
Study NCT04000555 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo twice a day prescribed for the duration of antibiotics
Study NCT01396993 — intervention group
Intervention type: PROCEDURE
Intervention: Breast Surgery
Description: breast conserving surgery AND immediate defect filling using local flaps (level I) or reduction plastics (level II) as well as mastectomy and immediate reconstruction using free flaps
Study NCT01396993 — intervention group
Intervention type: PROCEDURE
Intervention: Breast Surgery
Description: Breast conserving therapy without defect correction
Study NCT02693795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Description: A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003.
Study NCT02693795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
Study NCT03790748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lumbar Epidural Technique
Description: Standard Lumbar Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
Study NCT03790748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 25G Dural Puncture Epidural Technique
Description: 25G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
Study NCT03790748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25G Dural Puncture Epidural Technique
Description: 25G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
Study NCT03790748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 27G Dural Puncture Epidural Technique
Description: 27G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
Study NCT03790748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 27G Dural Puncture Epidural Technique
Description: 27G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
Study NCT01000597 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fluticasone furoate
Description: Seven inhaled doses of 200mcg FF given once daily in the morning (Part A; Days 1-7) followed by seven inhaled doses of 800mcg FF given once daily in the morning (Part B; Day 1 and Days 3-8, i.e. no dose on Day 2).~A single intravenous dose of 250mcg FF given over 20 minutes (Day 1).
Study NCT05108519 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study NCT03102320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/m2 IV administered on day 1 and day 8 of 21 day cycle, for up to maximum 6 cycles
Study NCT03102320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV administered on days 1 and 8 of a 21-day cycle
Study NCT03102320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (BAY94-9343)
Description: Anetumab ravtansine 6.5mg/kg IV in monotherapy indications. For combination indications, the MTD determined in safety lead in phase will be administered
Study NCT04443114 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Organ Donation Workshop
Description: Discussion Moderated by Peer Educators Didactic Session 1: Biomedical Aspects of Living Donation Didactic Session 2: Organ Donation and Transplantation in the US- Statistics and Procedures Moderated Debate: Living Organ Donation: Halal or Haram? Facilitated Group Discussions with Peer Educators
Study NCT04443114 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: End of Life Care Workshop
Description: Discussion Moderated by Peer Educators Didactic Session 1: Critical Theological Concepts about Sickness and Health in Islamic Bioethics Didactic Session 2: Islamic Rulings about Brain Death, and Withdrawing/Withholding Life Support Moderated Panel Discussion: End-of-life Decision Making Facilitated Group Discussions with Peer Educators
Study NCT01457001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25-OH-D vitamin
Study NCT02745236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner Led-Care
Description: Diagnosis and treatment plan decisions will be determined by Nurse Practitioner Led-Care.
Study NCT02745236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiologist Led-Care
Description: Diagnosis and treatment plan decisions will be determined as per usual care by the Cardiologist
Study NCT03615911 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine candidate MVA-MERS-S
Description: vaccination with MVA-MERS-S in two escalating dose regimes
Study NCT03303092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125
Description: TEV-48125 will be subcutaneously administered once monthly for 3 months.
Study NCT03303092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125 or placebo
Description: TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
Study NCT03303092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be subcutaneously administered once monthly for 3 months.
Study NCT01571648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral azacitidine
Description: Patients will receive 300 mg dose of oral azacitidine administered once daily for the first 21 days of each 28-day treatment cycle.
Study NCT02589795 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-C CN54ENV
Description: DNA plasmid containing the Clade C gp140 envelope gene from HIV-1 isolate CN54
Study NCT02589795 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CN54gp140
Description: Recombinant protein expressed from the Clade C gp140 envelope gene from HIV-1 isolate CN54
Study NCT02589795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigrid Delivery System - Intramuscular
Description: Electroporation
Study NCT02589795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigrid Delivery System - Intradermal
Description: Electroporation
Study NCT02385877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]4F-MHPG
Description: IV injection of \[18F\]4F-MHPG
Study NCT02385877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]3F-PHPG
Description: IV injection of \[18F\]3F-PHPG
Study NCT00735657 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: needle
Description: Peribulbar blockade with standard (25 mm) needle
Study NCT02476591 — intervention group
Intervention type: BEHAVIORAL
Intervention: Charge Transparency
Description: Providers caring for patients in the Charge Transparency cohort will be given access to patient specific charge data on a daily basis via an interactive dashboard which allows for full charge transparency to patients admitted to the Vanderbilt ICUs
Study NCT03136770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CK-30
Description: Compound K 600 mg
Study NCT03136770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red ginseng extracts
Description: Red ginseng extracts 2.94 g
Study NCT00735657 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: needle
Description: Peribulbar blockade with short (12.5 mm) needle
Study NCT02664532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Miller group
Description: Miller blade was used for laryngoscopy
Study NCT02664532 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Macintosh group
Description: Macintosh blade was used for laryngoscopy
Study NCT01085058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenograstim
Study NCT01594294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AOSEPT® Plus contact lens solution
Description: Hydrogen peroxide-based cleaning and disinfection system
Study NCT01594294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus® contact lens solution
Description: Polyaminopropyl biguanide (PHMB) preserved multipurpose solution
Study NCT01594294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etafilcon A contact lenses
Description: Hydrogel contact lenses worn on a daily wear basis for 14 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed every 2 weeks.
Study NCT01594294 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A contact lenses
Description: Hydrogel contact lenses worn on a daily wear basis for 14 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed every 2 weeks.
Study NCT01678872 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: RetinoStat
Description: Long Term Follow up of patients who received RetinoStat in a previous study
Study NCT00925886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acrysof Toric one-piece intraocular lens
Description: Cataract Surgery with a intraocular lens implantation
Study NCT00242359 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: omalizumab
Study NCT03718598 — intervention group
Intervention type: BEHAVIORAL
Intervention: Tendon and Nerve Gliding Exercises
Description: Tendon and Nerve Gliding Exercises: The tendon slip exercises used in this study were performed in five different positions, namely flexion, flat, hook, punch, table top and flat punch positions. Nerve-gliding exercises were performed by moving the fingers and wrists in six different positions, focusing on the median nerve consisting of all the disease grip, finger lengthening, wrist extension, thumb extension, forearm supination and gentle gentle gait. Instructions were given to make 10 sets of exercises in 3 sets, written and verbal, in order to have e exercises for all patient's tendons and nerves shifting exercises. Brochures were also provided explaining the exercises.
Study NCT02834598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-density electroencephalography
Description: Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
Study NCT02834598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-density electroencephalography
Description: Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
Study NCT00735657 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars Plana Vitrectomy
Description: Peribulbar block
Study NCT02982226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ReNu Injection
Description: ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
Study NCT01594294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lenses
Description: Hydrogel contact lenses worn on a daily wear basis for 14 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed every 2 weeks.
Study NCT01594294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lenses
Description: Silicone hydrogel contact lenses worn on a daily wear basis for 30 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed monthly.
Study NCT01594294 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lenses
Description: Silicone hydrogel contact lenses worn on a daily wear basis for 30 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed monthly.
Study NCT01594294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B contact lenses
Description: Silicone hydrogel contact lenses worn on a daily wear basis for 30 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed monthly.
Study NCT01594294 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: COMPLETE® MPS Easy Rub® Formula contact lens solution
Description: PHMB 0.0001% and poloxamer 0.05% multipurpose solution
Study NCT00305253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-pneumatic Anti-shock Garment (NASG)
Description: In the Post-Intrevention phase of the study, the NASG will be used when a patient meets the study criteria.
Study NCT04406051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine infusion and colloid preloading (NOR-COL)
Description: in parturients allocated to the NOR-COL group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive 5 mL/kg of colloid infusion prior to the initiation of spinal anesthesia
Study NCT04406051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine infusion and crystalloid co-loading (NOR-CRYST)
Description: in parturients allocated to the NOR-CRYST group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive 10 mL/kg of crystalloid infusion simultaneously with the initiation of spinal anesthesia
Study NCT02251444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: outpatient rehabilitation program
Study NCT02251444 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Study NCT04156932 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterine artery closure
Description: Interruption the uterine blood flow by closing the uterine artery at its cervical-isthmic part or at its origin.
Study NCT02982226 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: Corticosteroids are considered a standard of care for treatment of Plantar Fasciitis
Study NCT01480167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebral Augmentation (STABILIT)
Description: Vertebral Augmentation with the STABILIT Vertebral Augmentation System
Study NCT01480167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative Management
Description: Conservative Care
Study NCT03848455 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: genetic diagnosis
Description: The venous blood of the two groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and non-PD patients.
Study NCT02433405 — intervention group
Intervention type: BIOLOGICAL
Intervention: Fetuin-A
Description: Acute phase protein
Study NCT02523820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: Flixotide 1 mg + NSS upto 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
Study NCT02523820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NSS 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
Study NCT04480242 — intervention group
Intervention type: DRUG
Intervention: Inhaled Corticosteroids (ICs)
Description: Any corticosteroid (beclomethasone, budesonide, ciclesonide, fluticasone propionate, fluticasone furoate, mometasone, and triamcinolone) prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma. The daily dose of ICs prescribed will be translated into beclomethasone equivalent.
Study NCT04480242 — intervention group
Intervention type: DRUG
Intervention: Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA)
Description: Beclomethasone/formoterol, budesonide/formoterol, fluticasone furoate/vilanterol, fluticasone propionate/formoterol, fluticasone propionate/salmeterol, and mometasone/formoterol. Any of these combinations prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma.
Study NCT04480242 — intervention group
Intervention type: DRUG
Intervention: Other treatments
Description: Low-dose oral corticosteroids, long-acting muscarinic antagonist (tiotropium), low-dose macrolides (azithromycin), leukotrienes receptor antagonists (i.e. montelukast), or biologic agents (i.e. omalizumab).
Study NCT04480242 — intervention group
Intervention type: DRUG
Intervention: Inhaler device
Description: Pressurized metered-dose inhalers (pMDIs), Breath-actuated pMDIs, Dry powder inhalers (DPIs), Nebulizers, Soft Mist Inhalers.
Study NCT04480242 — intervention group
Intervention type: BEHAVIORAL
Intervention: Regularly monitoring of the Inhalation technique through mobile app
Description: App users are randomized within each pediatrician into two groups of equal size defined within the subsample recruited, so that 50% of the participants are allocated to answer the inhalation techniques, and the other 50% are allocated to answer the environment support scales. Once the app is downloaded, at month 2 and every 6 months thereafter the intervention group answers the inhalation techniques scale (group 1) and the control group answers the environment support scale (group 2).
Study NCT02300428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: oral iron
Description: BNF code for section 9.1.1.1 (Oral iron preparations for iron-deficiency anaemias)
Study NCT02604862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIB ONE
Description: FIB ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and two types of viewer software will be used to detect FIB ONE signal in the lung.
Study NCT02604862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AZD1236
Description: AZD1236 will be delivered at microdose concentrations and is thus considered to be unable to exert any pharmacologic effect outside the area of administration and unlikely to cause an adverse reaction.
Study NCT02748941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HITS quantification, Ultrasound examinations, High Resolution MRI
Description: Simultaneously measure the occurrence of the event (ischemic stroke) and the characteristics of the atheromatous plaque~Description of different modalities:~HITS quantification~Ultrasound examinations:~* Ulceration >2 mm~* Plaque thickness~* GSM: computer analysis after normalization of most informative longitudinal view (image with maximum plaque area) using Photoshop~* CEUS: plaque vascularization detection after bolus injection of SONOVUE on a video recording from the injection of the contrast (Vuebox - Bracco imaging)~High Resolution MRI:~* Stenosis severity, intraplaque hemorrhage, large lipid-rich necrotic core, ulceration or cap rupture and Brain MRI will be evaluated~* Quantification of shear stresses (Pa) on the surface of the plaque~mi-RNA identification and quantification
Study NCT02456181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JumpMath